Lieu de naissance
EDİRNE
Langues
İNGİLİZCE
Domaines d’intérêt médical
- Cancer du sein
- Cancers du système gastro-intestinal
- Cancer du poumon
- Cancers gynécologiques
- Cancers génito-urinaires
- Immunothérapie et thérapies ciblées
- Traitements personnalisés du cancer
À la une
La Dr Burçin Çakan Demirel (Maître assistante) est née à Edirne en 1989. Elle a achevé sa formation médicale à la faculté de médecine de l'Université Adnan Menderes en 2013.
Elle a effectué sa spécialisation en médecine interne au département de médecine interne de la faculté de médecine de l'Université Medipol d'Istanbul, devenant spécialiste en médecine interne en 2018. Elle a réalisé sa thèse de spécialisation sur les facteurs clinicopathologiques chez les patients atteints de cancer colorectal métastatique et leur impact sur le pronostic.
Après sa spécialisation en médecine interne, elle a accompli son service obligatoire en 2019 à l'hôpital public de Taşova (Amasya) et à l'hôpital municipal Fethi Sekin (Elazığ).
Elle a effectué sa surspécialisation en oncologie médicale au département d'oncologie médicale de la faculté de médecine de l'Université Pamukkale, devenant spécialiste en oncologie médicale en 2023.
Après sa spécialisation en oncologie médicale, elle a accompli son service obligatoire de 2023 à juillet 2025 à l'hôpital de formation et de recherche de Bağcılar.
À partir de juillet 2025, elle a commencé à exercer à l'Université Medipol d'Istanbul ; depuis janvier 2026, elle poursuit ses activités académiques et cliniques en tant que maître assistante au département de médecine interne de la faculté de médecine de l'Université Medipol d'Istanbul.
Elle est membre de plusieurs associations scientifiques nationales et internationales actives dans le domaine de l'oncologie, notamment l'Association turque d'oncologie médicale et l'European Society for Medical Oncology (ESMO).
Dans ses travaux scientifiques, elle mène des recherches sur les traitements systémiques de différentes tumeurs solides, l'évaluation de la réponse thérapeutique et les facteurs pronostiques. Le cancer du sein occupe une place importante parmi ses intérêts cliniques et académiques, et elle y a consacré plusieurs travaux scientifiques.
Elle a publié 40 articles scientifiques dans des revues scientifiques à comité de lecture nationales et internationales, et a présenté des communications orales et des posters lors de congrès scientifiques nationaux et internationaux.
Intégrant les avancées scientifiques actuelles dans sa pratique clinique, la Dr Çakan Demirel adopte des approches thérapeutiques personnalisées en oncologie, en évaluant conjointement la biologie tumorale, les caractéristiques de la maladie et les facteurs propres à chaque patient.
Expériences
2023 - 2025
Bağcılar Eğitim ve Araştırma Hastanesi
Uzm.Dr.
2019 - 2019
Amasya Taşova Devlet Hastanesi
Uzm.Dr.
2019 - 2019
Elazığ Fethi Sekin Şehir Hastanesi
Uzm.Dr.
Éducation
2023
Pamukkale Üniversitesi Tıp Fakültesi, Tıbbi Onkoloji
2018
İstanbul Medipol Üniversitesi Tıp Fakültesi, İç Hastalıkları
2013
Adnan Menderes Üniversitesi, Tıp Fakültesi
Publications
7.1. Uluslararası hakemli dergilerde yayınlanan makaleler (SCI & SSCI & Arts and Humanities)
Çakan B, Açikgöz O, Bilici A, Demir T, Oven BB, Hamdard J, Olmuşçelik O, Ölmez OF, Şeker M, Yıldız Ö. Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey. JBUON. 2021;26(5):1908-1917.
Goktas Aydin S, Cakan Demirel B, Bilici A, et al. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer. Curr Med Res Opin. 2022;38(10):1751-1758. doi:10.1080/03007995.2022.2108619
Demiray AG, Yaren A, Sungurtekin U, Baltalarli PB, Demirkan N, Herek D, Yapar Taskoylu B, Gokoz Dogu G, Degirmencioglu S, Ozgen U, Saginc H, Cakiroglu U, Ozhan N, Karan C, Cakan Demirel B, Dogan T, Ozdemir M. The effect of continuing chemotherapy after chemoradiotherapy during the time to surgery on tumor response and survival for local advanced rectal cancer. J Oncol. 2022;2022:4108677. doi:10.1155/2022/4108677
Acikgoz O, Cakan B, Demir T, et al. Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer. Medicine (Baltimore). 2021;100(44):e27712. doi:10.1097/MD.0000000000027712
Demiray AG, Demiray A, Yaren A, Yapar Taskoylu B, Gokoz Dogu G, Degirmencioglu S, Cakiroglu U, Ozhan N, Karan C, Cakan Demirel B, Dogan T, Ozdemir M. Evaluation of serum microRNA Let-7c and Let-7d as predictive biomarkers for metastatic pancreatic cancer. Turk J Gastroenterol. 2022;33(3):257–263. doi:10.5152/tjg.2022.21829
Karacin C, Oksuzoglu B, Demirci A, Keskinkilic M, Kose Baytemur N, Yilmaz F, Selvi O, Erdem D, Avsar E, Paksoy N, Demir N, Sezgin Goksu S, Turker S, Bayram E, Celebi A, Yilmaz H, Kuzu OF, Kahraman S, Gokmen I, Sakin A, Alkan A, Nayir E, Ugrakli M, Acar O, Erturk I, Demir H, Aslan F, Sonmez O, Korkmaz T, Celayir OM, Karadag I, Kayikcioglu E, Sakalar T, Oktem IN, Erenc T, Erul E, Eylemer Mocan E, Kalkan Z, Yildirim N, Ergun Y, Akagunduz B, Karakaya S, Kut E, Teker F, Cakan Demirel B,et al. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK4/6 inhibitor therapy. BMC Cancer. 2023;23(1):1261. doi:10.1186/s12885-023-11564-5
Karan C, Yaren A, Demirel BC, et al. Pretreatment PLR is preferable to NLR and LMR as a predictor in locally advanced and metastatic bladder cancer. Cancer Diagn Progn. 2023;3(6):706-715. doi:10.21873/cdp.10275
Kınıkoğlu O, Odabaş H, Altıntaş YE, Yıldız A, Çakan B, Akdağ G, Yıldırım S, Bal H, Kaya T, Tünbekici S, et al. Combining endocrine therapy with trastuzumab emtansine improves progression-free survival and overall survival in HER2-positive, hormone receptor-positive metastatic breast cancer. Medicina. 2024;60(6):951. doi:10.3390/medicina60060951
Kahraman S, Erul E, Gumusay O, Guven DC, Aksoy S, Basaran G, Seyyar M, Sahin E, Cabuk D, Bayram E, Paydas S, Cakan Demirel B, et al. Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) study. BMC Cancer. 2024;24(1):726. doi:10.1186/s12885-024-12347-3
Kahraman S, Erul E, Gumusay O, Guven DC, Aksoy S, Basaran G, Yaren A, Cakan Demirel B, et al. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age subgroups: Turkish Oncology Group (TOG) retrospective study. BMC Cancer. 2024;24(1):1275. doi:10.1186/s12885-024-12775-0
7.3. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler
Goktas Aydin S, Aydin A, Cakan Demirel B, Demir O, Bayramgil A, Kutlu O, Yildirim C, Aksoy A, Gulturk I, Taskaynatan H, Senocak Tasci E, Koseoglu C. A multi-center case-control study on osteoporosis risk in cancer patients receiving chemotherapy. J Clin Oncol. 2025;43(16_suppl):12033. doi:10.1200/JCO.2025.43.16_suppl.12033
CD4/6 İnhibitörü Kullanan Metastatik Hormon Pozitif Her2 Negatif Meme Kanserli Hastalarda Conut Skorunun Sağkalıma Etkisi AMORE-2022
Metastatik Safra Yolları Ve Safra Kesesi Kanserli Hastalarda Tedavi Öncesi Mutlak Lenfosit, Albumin, Hemoglobin, C-Reaktif Protein Ve Ldh Düzeylerinin Sağkalım Üzerine Etkisi Tek Merkez Deneyimi -TTOK 2022
7.4. Yazılan uluslararası kitaplar veya kitaplarda bölümler
7.5. Ulusal hakemli dergilerde yayınlanan makaleler ve bildiri kitabında basılan bildiriler
Yapar Taşköylü B, Avcı E, Demiray AG, Değirmencioğlu S, Gököz Doğu G, Yaren A, Ergin A, Kılıç D, Karan C, Çakan Demirel B, Doğan T, Özdemir M. Relationship between neutrophil/lymphocyte, platelet/lymphocyte, CRP/albumin ratio and survival in ovarian cancer. Pamukkale Medical Journal. 2021;14(3):763-769. doi:10.31362/patd.907695
Demiray AG, Yaren A, Yapar Taskoylu B, Degirmencioglu S, Gokoz Dogu G, Cakiroglu U, Ozhan N, Karan C, Cakan Demirel B, Dogan T, Ozdemir M. Should vitamin D level be measured before denosumab in patients with castration-resistant metastatic prostate cancer to prevent hypocalcemia? EJMI. 2021;5(3):313–316. doi:10.14744/ejmi.2021.48218
Göktaş Aydın S, Çakan Demirel B, Bilici A, Yılmaz C, Topçu A, Aykan MB, Kahraman S, Atcı MM, Akbıyık I, Akgül F, Ölmez ÖF, Aydın A. The optimal treatment approaches and prognostic factors in elderly patients with advanced stage biliary tract tumors (Metastatik safra yolu kanseri olan yaşlı hastalarda optimal tedavi yaklaşımları ve prognostik faktörler). Acta Oncologica Turcica. 2023;56:81-89. doi:10.5505/aot.2023.03708
Yapar Taskoylu B, Gokoz Dogu G, Cakan Demirel B, Sari T, Demiray AG, Degirmencioglu S, Yaren A, Ergin A, Avci E, Karan C, Dogan T, Ozdemir M. Evaluation of clinical, laboratory and treatment findings of oncology patients diagnosed with COVID-19 infection. EJMI. 2021;5(4):417–421. doi:10.14744/ejmi.2021.27607
Cakan Demirel B, Yaren A, Demiray AG, Yapar Taşköylü B, Doğan T, Özdemir M, Güçlü Kantar T, Karan C, Değirmencioğlu S, Gököz Doğu G. Prognostic significance of systemic immune inflammation indices and prognostic nutritional index before CDK4/6 inhibitor therapy in hormone receptor–positive, HER2–negative metastatic breast cancer patients. Pamukkale Med J. 2023;16(4):682-695. doi:10.31362/patd.1268419
Ozdemir M, Gokoz Dogu G, Yapar Taskoylu B, Demiray AG, Degirmencioglu S, Yaren A, Cakan Demirel B, Dogan T, Guclu Kantar T, Tas S, Acikgoz Yildiz B, Serin Ozel G, Mordag Cicek C. Prognostic value of a new marker, IBI score and NLR change in non-small cell lung cancer patients receiving immune checkpoint inhibitors (Prognostic value of IBI score and NLR change in NSCLC). Med J Mugla Sitki Kocman Univ. 2025;12(2):91-98. doi:10.47572/muskutd.1603917
Yapar Taskoylu B, Bir F, Demiray AG, Degirmencioglu S, Gokoz Dogu G, Yaren A, Ergin A, Karan C, Cakan Demirel B, Dogan T, Ozdemir M, Guclu Kantar T. The association of mismatch-repair (MMR) deficiency with tumor infiltrating lymphocytes and survival in patients with ovarian cancer. EJMA. 2024;4(1):22–27. doi:10.14744/ejma.2023.74946
Dogan T, Yaren A, Demiray AG, Yapar Taskoylu B, Cakan Demirel B, Ozdemir M, Guclu Kantar T, Degirmencioglu S, Gokoz Dogu G. The effect of pre-treatment inflammatory response markers on survival in locally advanced unresectable and metastatic gastric cancer: a retrospective cross-sectional study. Pamukkale Med J. 2024;17(2):XXX–XXX. doi:10.31362/patd.1265291
Kahraman S, Hizal M, Gumusay O, Basaran G, Seyyar M, Sahin E, Cabuk D, Yasar A, Bayoglu IV, Bayram E, Paydas S, Gulbagci B, Hacibekiroglu I, Cakan Demirel B, et al. HER2-low expression in patients with hormone receptor-positive and HER2-negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy. Turk J Clin Lab. 2024;15(2):255–262. doi:10.18663/tjcl.1639022
Ozdemir M, Gokoz Dogu G, Yapar Taskoylu B, Demiray AG, Degirmencioglu S, Yaren A, Arslan M, Cakan Demirel B, Dogan T, Guclu Kantar T, Tas S, Acikgoz Yildiz B, Serin Ozel G, Mordag Cicek C. Use of albumin and CRP-related immuno-nutritional markers for prediction of locoregional response to treatment in unresectable hepatocellular carcinoma. Pamukkale Med J. 2025;18(1):87–97. doi:10.31362/patd.1471860
Ozdemir M, Gokoz Dogu G, Yapar Taskoylu B, Yaren A, Degirmencioglu S, Demiray AG, Erdemir A, Cakan Demirel B, Dogan T, Guclu Kantar T, Tas S, Acikgoz Yildiz B, Serin Ozel G, Mordag Cicek C. The impact of SARS-CoV-2 infection on the survival in NSCLC patients undergoing immunotherapy. Pamukkale Med J. 2025;18(4):733–747. doi:10.31362/patd.1598359
7.7. Diğer yayınlar
Cakan Demirel B. Febril kanser hastasında ampirik antibiyotik tedavisi. In: Soylu HM, Sedef AM, eds. Kanser ve Enfeksiyon. Ankara: Akademisyen Kitabevi; 2023:117–126. doi:10.37609/akya.2853. ISBN 9786253994051.
Cakan Demirel B. Kanser hastasında atriyal fibrilasyon. In: Baysal E, Okşul M, Şener YZ, eds. Atriyal Fibrilasyon Tanı ve Tedavisine Güncel Yaklaşım. Ankara: Akademisyen Kitabevi; 2023:197–206.
Cakan Demirel B. Kanser tedavisi ilişkili hipertansiyon ve tedavisi. In: Dilmen Y, ed. Hipertansiyon Tanı ve Tedavisine Güncel Yaklaşım. Ankara: Akademisyen Kitabevi; 2023:311–321. doi:10.37609/akya.607. ISBN 9786257496025.